Cancer

News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.

Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.

The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.

The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.

The companies will integrate DNAmito's Prodecis into Varian's 360 Oncology care management software to deliver genomics-based evidence to guide radiation therapy in cancer.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.

Dec
14
Sponsored by
N-of-one

About one year ago, the Association for Molecular Pathology (AMP), with liaison representation from the American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP), released a guideline on reporting somatic cancer variants.